Add this topic to your myFT Digest for news straight to your inbox
Congressional probe found 22 consultants had advised both the US FDA and drug manufacturers over a decade
FDA’s green light for aducanumab may delay development of more effective treatments for dementia, critics say
Agency that controls spending by government health schemes will not fund drug for most patients
UK drugmaker’s R&D chief says abandoning market would have little impact
US drugs regulator says it needs more time to evaluate low-dose jab for children under 5
After decades of false starts, scientists are beginning to believe that modified organs from animals can help solve the global shortage
GSK product given as few as six times a year while current regimen requires daily pills
Concerns raised over Robert Califf’s previous stint at the US drugs regulator and its approach to the opioid epidemic
Food and Drug Administration had previously limited third doses to those who were vulnerable
US expected to become first country to authorise vaccine for younger children
Data from drugmaker and US regulator suggest advantages of Covid-19 jab would far outweigh risks
People at high risk of catching coronavirus can now receive any of three vaccines authorised by US health agency
Regulator signals it will allow devices to help smokers quit but not flavours popular with teens
Panel recommends third jabs for vulnerable people in step towards expanding US rollout of extra doses
Ivermectin has been touted by conservative commentators despite not being approved for use against virus
Agency decision to restrict third jabs to vulnerable Americans deals blow to Biden’s strategy
Advisory committee endorses third dose only for elderly and at-risk groups in blow to Biden
Data come as US regulator weighs approval for booster shot to bolster immunity
Pair who left agency two weeks ago among authors of scathing critique in academic journal
US president’s message comes after first full approval for a Covid-19 shot by the Food and Drug Administration
FDA says additional dose of Pfizer or Moderna can be given to those who are immunocompromised
Pharma group blames ‘misinformation’ for overshadowing approval of therapy
US drugs watchdog was under pressure after scientific outcry over controversial Biogen treatment
US regulator’s approval of controversial treatment shows it is too close to Big Pharma, say critics
Top US drug regulator is accused of being too cosy with industry after approving Alzheimer’s drug
International Edition